Comparative Analysis of Maintenance Treatments in Patients with Newly Diagnosed Advanced Ovarian Cancer After First-Line Platinum-Based Regimens.

ABSTRACT:

Background

Poly (ADP-ribose) polymerase inhibitors (PARPi) are the standard of care for first-line maintenance in advanced ovarian cancer, but their benefit varies by BRCA and homologous recombination deficiency (HRD) status, and no head-to-head comparisons are available.

Methods

We conducted an indirect comparison of PARPi regimens using reconstructed individual patient data (IPD) from Kaplan-Meier curves of phase III randomized trials (SOLO1, PRIMA, PAOLA1, ATHENA, FLAMES). Progression-free survival (PFS) was the primary endpoint; overall survival (OS) was exploratory. Subgroups were defined as BRCA-mutated (BRCA+), BRCA-/HRD+, and BRCA-/HRD-. Safety outcomes were assessed through a network meta-analysis of adverse drug reactions (ADRs).

Results

In BRCA+ patients, o

SUBMITTER: Gasperoni L 

PROVIDER: S-EPMC12651439 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature